Not Yet RecruitingNot Applicable

DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death

10 participantsStarted 2025-05

Plain-language summary

The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is: Does DNA methylation changes distinguish Brugada patients from healthy controls? Does DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease. * \>18 years * Unrelated patients Exclusion Criteria: * Related patients * Not type 1 Br patter

What they're measuring

Number of differentially methylated genes as assessed by EPIC microarray

Timeframe: 3 months

Trial details

NCT IDNCT06888271

SponsorUniversity of Campania Luigi Vanvitelli

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-02

Contact for this trial

Giuditta Benincasa, PhD

0815667916 giuditta.benincasa@unicampania.it

View on ClinicalTrials.gov More Brugada Syndrome trials